

CORRECTION

Correction: Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line

Andreas Agathangelidis, Lydia Scarfò, Federica Barbaglio, Benedetta Apollonio, Maria Teresa Sabrina Bertilaccio, Pamela Ranghetti, Maurilio Ponzoni, Gabriella Leone, Valeria De Pascali, Lorenza Pecciarini, Paolo Ghia, Federico Caligaris-Cappio, Cristina Scielzo



OPEN ACCESS

Citation: Agathangelidis A, Scarfò L, Barbaglio F, Apollonio B, Bertilaccio MTS, Ranghetti P, et al. (2015) Correction: Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line. PLoS ONE 10(7): e0134748. doi:10.1371/journal.pone.0134748

Published: July 29, 2015

Copyright: © 2015 Agathangelidis et al. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Table 1. “Detailed immunogenetic, genetic and cell phenotype information of the PCL12 cell line and comparison to the respective properties of the MEC1 and MEC2 cell lines,” is missing a column. Please see the corrected Table 1 here.

		PCL12	MEC1	MEC2
Immunogenetics	IGH rearrangement	V3-30-3 D2-15 J6	V4-59 D2-21 J4	
	IGHV mutation status	100%	94.65%	
	VH CDR3	AREGALAGDIVVVVAANYYYYYGMDV	ARSQGVLTIDY	
	VH CDR3 length	26	12	
	IGL rearrangement	Igλ (V2-8 J2/3)	Igκ (V4-1 J2)	
Genetics	NOTCH1	no mutations	c.7544_7545delCT	-
	SF3B1	no mutations	no mutations	-
	TP53	R72 polymorphism	R72 polymorphism	-
		c.521C>G, p.P174T	c.949_950insC	-
	MYD88	no mutations	no mutations	-
	del17p13	no	yes	-
Cell markers	CD5	95%	0%	0%
	CD10	0%	0%	0%
	CD19	100%	99%	99%
	CD20	92%	96%	96%
	CD22	98%	76%	67%
	CD23	90%	89%	36%
	CD27	98%	99%	-
	CD38	78%	90%	99%
	CD45	97%	99%	92%
	CD80	35%	98%	91%
	CD83	40%	4%	-
	CD95	90%	90%	63%
	CD200	26%	0%	-
	IgD	54%	97%	99%
	IgM	50%	99%	94%
	HLA-DR	43%	99%	97%
	FMC7	0%	8%	72%
	ZAP70	37%	18%	-
	CXCR4	9%	5%	-
	CXCR5	42%	12%	-
VLA4	90%	98%	-	
CD54	72%	98%	98%	
p-ERK	87%	Positive WB ²⁸	-	

doi:10.1371/journal.pone.0134748.t001

Reference

1. Agathangelidis A, Scarfò L, Barboglio F, Apollonio B, Bertilaccio MTS, Ranghetti P, et al. (2015) Establishment and Characterization of PCL12, a Novel CD5+ Chronic Lymphocytic Leukaemia Cell Line. PLoS ONE 10(6): e0130195. doi:[10.1371/journal.pone.0130195](https://doi.org/10.1371/journal.pone.0130195) PMID: [26110819](https://pubmed.ncbi.nlm.nih.gov/26110819/)